Beyond The Numbers: 11 Analysts Discuss ACADIA Pharmaceuticals Stock

Benzinga Insights

September 29, 2025

Benzinga

In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide array of perspectives from bullish to bearish.

Latest Ratings for ACAD

Date	Firm	Action	To
Mar 2022	Cantor Fitzgerald	Maintains	Overweight
Mar 2022	Goldman Sachs	Maintains	Neutral
Mar 2022	Mizuho	Maintains	Neutral

View More Analyst Ratings for ACAD

View the Latest Analyst Ratings

Market Impact

Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields

October 7, 2025

Benzinga

Market Impact

This Spire Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

October 7, 2025

Benzinga

Market Impact

EXCLUSIVE: Envoy Medical Cuts Capital Needs After FDA Approval For Final Trial Stage Of Cochlear Implant Trial

October 7, 2025

Benzinga

Market Impact

Tuya Accelerates AI Strategy

September 5, 2025

Benzinga

Market Impact

BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data

September 5, 2025

Benzinga

Market Impact

This Twilio Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

September 5, 2025

Benzinga

Equities

Kinder Morgan Surges 30% in a Year: Risks to Consider Before Jumping In

August 19, 2025

Barchart

Markets

Lebanon’s Bonds Escape Infamous 20-Cent Club as Reform Bets Grow

September 3, 2025

Bloomberg

Markets

Denmark Targets $1.56 Billion With First European Green Bond

September 3, 2025

Bloomberg

Enjoy premium content in your inbox.

You're in! Check your email to learn more.

Oops! Something went wrong while submitting the form.

Beyond The Numbers: 11 Analysts Discuss ACADIA Pharmaceuticals Stock

Latest Ratings for ACAD

More from

Benzinga

More

Market Impact

Articles

Trending News

Enjoy premium content in your inbox.

News

Tools

More

Follow